VMCVM Regional Access Center Work Plan: During the 2022-2023project year,The regional center at VMCVM will continue to support the essential tasks of the national FARAD program outlined below,provide pharmacokinetic services to all FARAD sites, and continue developing pharmacokinetic model tools that allow FARADresponders to fully utilize published studies to avoid meat and milk violative residues in food animals. The primary focus areas ofthe VMCVM FARAD component for 2022- 2023are as follows: (1) strengthen the response team via the hiring of a veterinarypharmacology resident and graduate student (Dr. Mercer) and, in collaboration with NCSU and UC Davis, provide drug andchemical residue management expertise to veterinarians by answering telephone and internet inquiries; (2) collaborate withNCSU, KSU-Olathe, UC Davis, and University of Florida, to validate (via LC-MS/MS sample analysis) many of our computational estimates of a safewithdrawal time.Respond to drug and chemical residue casesThe VMCVM FARAD Regional Access Center will continue in collaboration with NCSU and UC-Davis FARAD Regional AccessCenter to answer residue avoidance inquiries. This service will require the veterinary clinical pharmacology expertise of Dr.Jennifer Davis and a Veterinary Pharmacology Resident/PhD student, Dr. Melissa Mercer (DVM, MS). Dr. Mercer will beresponsible for daily management of cases at VMCVM. This will facilitate the accuracyand timeliness of FARAD's response to as many as 70 cases a week. VMCVM will also collaborate and contribute to writingtimely FARAD Digests that focus on the management of the more common drug residue scenarios facing food animalveterinarians. We will collaborate in outreach programs to producer groups and veterinary specialty groups such as AVMA,AABP, AAVPT. Dr. Davis is the current Secretary of AAVPT and is uniquely positioned to ensure continued collaborationbetween AAVPT and FARAD. The VMCVM also has a long-standing relationship with the FDA Center for Veterinary Medicinethrough providing externship opportunities for students and potentially FARAD graduate students/residents. Our proximity to theFDA facilities is a great advantage in this area.Pharmacokinetic TrialsVMCVM will collaborate with UF,NCSU and UC-Davis to obtain in vivo data to validate FARAD approved withdrawalinterval commendations. This will be accomplished by analysis obtained fromin vivo pharmacokinetic studies in food producing animalsto determine detection times of drug in products such as eggs, milk or tissues. VMCVM has a fully equippedPharmacology/Toxicology laboratory that will complement facilities currently in use at NCSU and UC-Davis.